Cue Biopharma, Inc. 8-K

What Happened

• Cue Biopharma, Inc. (CUE) filed an 8-K reporting that on February 9, 2026 the Board appointed Lucinda Warren as Chief Financial and Business Officer. Upon appointment, Ms. Warren assumed the duties of the company’s principal financial officer and principal accounting officer. The filing was signed on February 12, 2026.

Key Details

• Appointment effective date: February 9, 2026.
• Ms. Warren (age 57) has served as Cue’s Chief Business Officer since September 2024 and has over 30 years in pharma/biotech.
• Prior role: Vice President, Business Development (Neuroscience & Japan) at Johnson & Johnson, 2014–2024.
• Compensation/agreements: No additional compensation or material changes to her employment agreement; she will continue existing benefits and plans. No related-party or family relationships or reportable transactions under Item 404(a) of Regulation S-K.

Why It Matters

• Investors should note Cue has consolidated financial and business leadership by naming an internal executive as the company’s principal financial and accounting officer, which centralizes responsibility for finance and business development oversight.
• The filing indicates this change was administrative (no extra pay or contract changes disclosed), implying limited immediate financial impact, while potentially affecting internal reporting and investor communications going forward.